This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
7 Low Price-to-Book Stocks Worth Buying in July
by Kinjel Shah
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.
Thermo Fisher's (TMO) Rapid DNA Solution Gets FBI Approval
by Zacks Equity Research
Thermo Fisher's (TMO) RapidHIT ID DNA Booking System allows seamless integration of Rapid DNA into the law enforcement booking agency process.
Here's Why You Should Add LabCorp (LH) Stock to Your Portfolio
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) backed by strong diagnostic arm growth and improvement in base business.
Smith+Nephew's (SNN) New Device to Boost Patient Outcomes
by Zacks Equity Research
Smith+Nephew's (SNN) FAST-FLIX FLEX Meniscal Repair System to provide long-term benefits to patients.
Here's Why You Should Retain Merit Medical (MMSI) Stock Now
by Zacks Equity Research
Merit Medical (MMSI) continues to gain traction from robust Peripheral Intervention arm and solid international presence. Forex, although, remains a concern.
Walgreens (WBA), VillageMD State 2021 Primary Healthcare Goal
by Zacks Equity Research
With this Walgreens (WBA) and VillageMD are on track to achieve their January 2021 goal of opening at least 600 Village Medical primary care practices in more than 30 U.S. markets over the next four years.
QIAGEN's (QGEN) NeuMoDx HAdV Quant Assay Wins CE-IVD Mark
by Zacks Equity Research
QIAGEN's (QGEN) NeuMoDx solutions at present offer CE-IVD tests for various viral and bacterial pathogens.
Amedisys' (AMED) VNA Assets Buyout Boosts Home Health-Hospice
by Zacks Equity Research
Leveraging on VNA's home health and hospice care legacy, Amedisys (AMED) expects to provide additional scale and resources.
Thermo Fisher (TMO) Introduces CoE in Clinical Metabolomics
by Zacks Equity Research
Thermo Fisher's (TMO) new research collaboration is aimed to provide the metabolomics community with advanced, best practices and standard operating procedures.
Here's Why You Should Retain AmerisourceBergen (ABC) Now
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment.
Medtronic's (MDT) DEFINE AFib Study to Assess AF Burden
by Zacks Equity Research
Medtronic (MDT) begins first app-based study to understand atrial fibrillation burden in patients, utilizing data collected from the LINQ range of insertable cardiac monitors.
IDEXX Laboratories (IDXX) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Strong sales at the CAG and LPD arms are driving the top line for IDEXX Laboratories (IDXX).
Here's Why You Should Add STERIS (STE) to Your Portfolio
by Zacks Equity Research
Investors are optimistic about STERIS (STE) owing to strong segmental performance and bullish 2022 outlook.
QIAGEN (QGEN) Faces COVID-Support Sales Drop, Huge Debt
by Zacks Equity Research
With gradually falling COVID-19 cases, since the beginning of 2021, QIAGEN's (QGEN) COVID-19 testing related product lines are seeing significant decline in sales.
Surmodics (SRDX) Boosts Portfolio With Vetex Medical Buyout
by Zacks Equity Research
Surmodics' (SRDX) buyout of Vetex Medical adds second FDA 510 (k) cleared device to its thrombectomy platform.
Here's Why You Should Retain McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from its robust Distribution Solutions segment.
Bio-Rad (BIO)-Seegene Pact to Provide Diagnostic Suit In U.S.
by Zacks Equity Research
Bio-Rad (BIO) and Seegene team up to develop and commercialize molecular diagnostic products in the United States.
Abbott's (ABT) DAPT for High Bleeding Risk Gets FDA Approval
by Zacks Equity Research
Abbott's (ABT) DAPT can be discontinued safely early as short as 28 days with no higher risk in patient adverse events.
Myriad Genetics (MYGN) Divests Myriad RBM to Focus on Core Units
by Zacks Equity Research
Myriad Genetics' (MYGN) new divesture will enable company to accelerate the execution of transformation plan and drive growth.
NVST vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NVST vs. BSX: Which Stock Is the Better Value Option?
Abbott (ABT) Reports Late-Breaking Data on FreeStyle Libre
by Zacks Equity Research
Late-breaking data on Abbott's (ABT) FreeStyle Libre system demonstrates improvement in health and equity outcomes for diabetes patients.
QIAGEN (QGEN) & Verogen Team Up to Employ NGS-Based Forensics
by Zacks Equity Research
QIAGEN's (QGEN) new collaboration will offer customers advanced tools and comprehensive support for HID workflows in laboratories.
Charles River (CRL) Advances in Gene Therapy With Vigene Buyout
by Zacks Equity Research
The consolidation between Charles River (CRL) and Vigene is set to establish an end-to-end, gene-modified cell therapy solution in the United States.
Here's Why You Should Buy National Vision (EYE) Stock Now
by Zacks Equity Research
Investors remain optimistic about National Vision (EYE) on increased eyeglass comparable demand and encouraging 2021 strategies.
Medtronic (MDT) Diabetes Arm Grows With Favorable InPen Data
by Zacks Equity Research
Medtronic's (MDT) InPen is a FDA as well as CE Mark-cleared smart insulin pen available for patients who require multiple daily injections.